Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share. Kevin Hrusovsky, CEO of Quanterix, was with us to discuss how the company plans to revolutionize healthcare. The fourth-leading cause of death is drug side effects, and drugs only work half the time, says Hrusovsky. He believes that if you can personalize the drugs, you have an opportunity to improve the whole pharmaceutical industry. Quanterix is developing technology that will digitize how they see into blood, and help to see disease long before there are symptoms. Rocket science is being deployed into the blood, says Hrusovsky. He says that if you can see biomarkers and incorporate into fitbits, it can really help improve health.

Share:
More In Science
Apple and Tesla, a Perfect Fit?
Gene Munster thinks so. The managing partner at Loup Ventures said Tim Cook could help rein in the ambitions of Elon Musk. But a merger won't be likely unless Tesla runs into real financial troubles.
Kathy Ireland Talks Her Brand's Step Into CBD
Kathy Ireland, Chief Brand Strategist of Level Brands, spoke with Cheddar about her company's dive into the CBD market. Shares of cannabis companies have been soaring as momentum grows for wide marijuana legalization.
Latest Investment Products Use A.I. to Analyze Market Trends
AIEQ is the first ETF to apply artificial intelligence throughout the investment process, using social media and news trends in addition to taking information from the stock market. Art Amador of EquBot explains how A.I. can help investors make better decisions.
Lyft Wants Everyone to Stop Owning Cars
Lyft says it has completed 5,000 rides in its autonomous vehicle pilot program in Las Vegas. Taggart Matthiesen, the company's head of product, told Cheddar that customers are starting to acclimate to the idea of a self-driving ride, but it will be a while before safety drivers are unnecessary.
Load More